Dr Reddy’s launches Reddy-Lenalidomide

Reddy-Lenalidomide capsules are available in 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg strengths

98
Medicine Capsule
Picture: Pixabay

Last Updated on September 5, 2021 by The Health Master

Dr Reddy’s Laboratories yesterday launched Reddy-Lenalidomide, a generic equivalent to Revlimid (lenalidomide) capsules in the Canadian market.

The product is approved by Health Canada, the company notified in a statement.

Speaking in this regard, Vinod Ramachandran, PhD, Vice President and General Manager, Dr Reddy’s Laboratories Canada, said, “Our launch of Reddy-Lenalidomide represents our firm commitment to providing access to affordable medicines for Canada’s Multiple Myeloma and Myelodysplastic Syndrome (MDS) patient population.”

He also said, “Along with this important launch, we are pleased to introduce our Reddy2Assist Platform, which provides convenient one-stop access to assist prescribers and pharmacists with qualification requirements for patients, as well as patient onboarding and registration via web portal, telephone or fax.”

Reddy-Lenalidomide capsules are available in 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg strengths, each in blister packs, the statement said.

Lupin launches drug for Asthma patient

Merck launches Pergoveris Pen for Infertility treatment in India

Alkem launches Ibuprofen, Famotidine tablets

Zydus Cadila gets final nod from USFDA for Fulvestrant injection

USFDA inspection ends with ‘Zero’ observations: Alkem

Granules Pharma clears USFDA audit

DCGI asks State FDAs to restrict Tolperisone FDC for these usage…

Govt to include ICD as depot to import Drugs under Drugs…

NLEM: New list of Essential Medicines: 39 new drugs added, 16…

Granules India gets license from DRDO for Covid drug 2-DG

Pharma Industry urges Govt to include Chile under PLI scheme

Latest Notifications regarding Pharmaceuticals

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner